Zobrazeno 1 - 10 of 102 pro vyhledávání: '"S G, Eckhardt"'
1
Akademický článek
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
Autor: A. Capasso, J. Lang, T. M. Pitts, K. R. Jordan, C. H. Lieu, S. L. Davis, J. R. Diamond, S. Kopetz, J. Barbee, J. Peterson, B. M. Freed, B. W. Yacob, S. M. Bagby, W. A. Messersmith, J. E. Slansky, R. Pelanda, S. G. Eckhardt
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Abstract Background The success of agents that reverse T-cell inhibitory signals, such as anti-PD-1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only a minority of patients respond to single-agent therapies, method
Externí odkaz: https://doaj.org/article/1b0a6ba7e4cd45abb960b2838d0cd8c9
Zobrazit plný text záznamu
2
Akademický článek
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
Autor: Jennifer R. Diamond, S. G. Eckhardt, Todd M. Pitts, Adrie van Bokhoven, Dara Aisner, Daniel L. Gustafson, Anna Capasso, Sharon Sams, Peter Kabos, Kathryn Zolman, Tiffany Colvin, Anthony D. Elias, Anna M. Storniolo, Bryan P. Schneider, Dexiang Gao, John J. Tentler, Virginia F. Borges, Kathy D. Miller
Publikováno v: Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background Triple-negative breast cancer (TNBC) remains an aggressive breast cancer subtype with limited treatment options. ENMD-2076 is a small-molecule inhibitor of Aurora and angiogenic kinases with proapoptotic and antiproliferative acti
Externí odkaz: https://doaj.org/article/b8114fdcf25045a88513879cfaf4520b
Zobrazit plný text záznamu
4
Lectures
Autor: D. S. Chen, D. M. Feltquate, F. Smothers, A. Hoos, S. Langermann, S. Marshall, R. May, M. Fleming, F. S. Hodi, A. Senderowicz, K. G. Wiman, S. de Dosso, W. Fiedler, L. Gianni, S. Cresta, H. B. Schulze-Bergkamen, L. Gurrieri, M. Salzberg, B. Dietrich, A. Danielczyk, H. Baumeister, S. Goletz, C. Sessa, D. Strumberg, B. Schultheis, A. Santel, F. Gebhardt, W. Meyer-Sabellek, O. Keil, K. Giese, J. Kaufmann, M. Maio, G. Choy, A. Covre, G. Parisi, H. Nicolay, E. Fratta, E. Fonsatti, L. Sigalotti, S. Coral, P. Taverna, M. Azab, E. Deutsch, C. Lepechoux, J. P. Pignon, Y. T. Tao, S. Rivera, B. C. Bourgier, M. Angokai, R. Bahleda, K. Slimane, E. Angevin, B. B. Besse, J. C. Soria, K. Dragnev, J. H. Beumer, B. Anyang, T. Ma, F. Galimberti, C. P. Erkmen, W. Nugent, J. Rigas, K. Abraham, D. Johnstone, V. Memoli, E. Dmitrovsky, E. E. Voest, L. Siu, F. Janku, A. Tsimberidou, R. Kurzrock, J. Tabernero, J. Rodon, R. Berger, A. Onn, G. Batist, C. Bresson, V. Lazar, J. J. Molenaar, J. Koster, M. Ebus, D. A. Zwijnenburg, P. van Sluis, F. Lamers, L. Schild, I. van der Ploeg, H. N. Caron, R. Versteeg, J. Pouyssegur, I. Marchiq, J. Chiche, D. Roux, R. Le Floch, S. E. Critchlow, R. F. Wooster, S. Agresta, K. E. Yen, P. A. Janne, E. R. Plummer, G. Trinchieri, L. Ellis, S. L. Chan, W. Yeo, A. T. Chan, F. Mouliere, S. El Messaoudi, C. Gongora, P. J. Lamy, M. del Rio, E. Lopez-Crapez, B. Gillet, M. Mathonnet, D. Pezet, M. Ychou, A. R. Thierry, V. Ribrag, W. Vainchenker, S. Constantinescu, H. Keilhack, I. A. Umelo, A. Noeparast, G. Chen, M. Renard, C. Geers, J. Vansteenkiste, E. Teugels, J. de Greve, O. Rixe, X. Qi, Z. Chu, J. Celerier, L. Leconte, N. Minet, J. Pakradouni, B. Kaur, F. Cuttitta, A. J. Wagner, Y. X. Zhang, E. Sicinska, J. T. Czaplinski, S. P. Remillard, G. D. Demetri, S. Weng, L. Debussche, L. Agoni, E. P. Reddy, C. Guha, K. Silence, A. Thibault, H. de Haard, T. Dreier, P. Ulrichts, M. Moshir, S. Gabriels, J. Luo, C. Carter, A. Rajan, S. Khozin, A. Thomas, A. Lopez-Chavez, C. Brzezniak, L. Doyle, C. Keen, M. Manu, M. Raffeld, G. Giaccone, S. Lutzker, J. M. Melief, S. G. Eckhardt, L. Trusolino, G. Migliardi, E. R. Zanella, F. Cottino, F. Galimi, F. Sassi, S. Marsoni, P. M. Comoglio, A. Bertotti, M. Hidalgo, S. J. Weroha, P. Haluska, M. A. Becker, S. C. Harrington, K. M. Goodman, S. E. Gonzalez, M. al Hilli, K. A. Butler, K. R. Kalli, A. L. Oberg, I. J. Huijbers, R. Bin Ali, C. Pritchard, M. Cozijnsen, N. Proost, J. Y. Song, P. Krimpenfort, E. Michalak, J. Jonkers, A. Berns, U. Banerji, A. Stewart, P. Thavasu, S. Banerjee, S. B. Kaye
Publikováno v: Annals of Oncology. 24:i7-i17
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::035ed0eff9eb1a7df4f5f8bb1d940b6b
https://doi.org/10.1093/annonc/mdt042
Zobrazit plný text záznamu
5
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors
Autor: S. G. Eckhardt, Howard A. Burris, J. Li, J. R. Infante, K. Wu, Anna Osmukhina, Dennis Huszar, Razelle Kurzrock, J. Spratlin, Jeffrey M. Skolnik, Roy S. Herbst, L. Hylander-Gans
Publikováno v: Cancer Chemotherapy and Pharmacology. 69:165-172
Inhibition of kinesin spindle protein or Eg5 causes the formation of monoastral mitotic spindles, which leads to cell death. AZD4877 is a specific, potent inhibitor of Eg5. This was a Phase I, open-label, two-part study to evaluate the maximum tolera
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18cf97f26d6f3624656824a9e57e7ae
https://doi.org/10.1007/s00280-011-1667-z
Zobrazit plný text záznamu
6
Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study
Autor: Jelena Klawitter, Uwe Christians, Dieter Leibfritz, Nora Anderson, S. G. Eckhardt, Natalie J. Serkova
Publikováno v: British Journal of Cancer
The goal of this study was to evaluate the time course of metabolic changes in leukaemia cells treated with the Bcr-Abl tyrosine kinase inhibitor imatinib. Human Bcr-Abl(+) K562 cells were incubated with imatinib in a dose-escalating manner (starting
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93b954639970cb2409ea34a80e5eca84
https://doi.org/10.1038/sj.bjc.6604946
Zobrazit plný text záznamu
7
Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors
Autor: Michele Basche, D Gallemann, Scott N. Holden, Dimitrios Colevas, S. G. Eckhardt, Anna E. Barón, Cindy L. O'Bryant, D Davis, C Zang, Mark Morrow, Lia Gore, Daniel L. Gustafson, S. Hariharan, D McConkey
Publikováno v: Annals of Oncology. 18:1400-1407
Background Cilengitide, an antiangiogenic agent that inhibits the binding of integrins alpha(nu)beta(3) and alpha(nu)beta(5) to the extracellular matrix, was studied at two dose levels in cancer patients to determine the optimal biological dose. Pati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4f5bb8b35158c203d56505e0d825059
https://doi.org/10.1093/annonc/mdm140
Zobrazit plný text záznamu
8
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors
Autor: PA Palmer, S. G. Eckhardt, Cindy L. O'Bryant, A. S. Pierson, Roger B. Cohen, Lia Gore, C Mikule, Steven Zhang, Scott N. Holden, Mark Morrow, M Persky, Daniel L. Gustafson
Publikováno v: Annals of Oncology. 17:1709-1717
BACKGROUND To evaluate the toxicity and pharmacological and biological properties of the farnesyl protein transferase (FPTase) inhibitor, tipifarnib (R115777, ZARNESTRAtrade mark) and capecitabine administered for 14 days every 3 weeks. PATIENTS AND
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8660cb126ff1d783ec2919af70380f7
https://doi.org/10.1093/annonc/mdl282
Zobrazit plný text záznamu
10
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors
Autor: Maria Pia Morelli, Giampaolo Tortora, Michele Orditura, Tina Cascone, Fortunato Ciardiello, Teresa Troiani, S. G. Eckhardt, F. De Vita, G. Laus, Stefano Pepe
BACKGROUND: Epidermal growth factor receptor (EGFR) inhibitors are in clinical development in cancer treatment. Preclinical studies have shown potential antitumor efficacy of these agents in combination with chemotherapy or with radiotherapy. However
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6bb1c038018a1370ef717e300430bec
http://hdl.handle.net/11386/3104430
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje